Beyond Perfusion: Cerebral Vascular Reactivity and Assessment of Microvascular Permeability

Topics in Magnetic Resonance Imaging

Volumn 15, Issue 1, 2004, Pages 58-65

  Kassner, Andrea ^a,c   Roberts, Timothy P L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

BOLD; CVR; Microvascular permeability; MR; Pharmacokinetic modeling

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOTERIDOL;

BLOOD VESSEL PERMEABILITY; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; HUMAN; MATHEMATICAL MODEL; MICROVASCULARIZATION; PRIORITY JOURNAL; REVIEW; VASODILATATION;

CAPILLARY PERMEABILITY; CARBON DIOXIDE; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; OXYGEN; RESPIRATION; VASODILATION;

EID: 1842615861     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200402000-00006     Document Type: Review

References (47)

1. Gueckel F, Brix G, Rempp KA, et al. Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient echo imaging. J Comp Assist Tomogr. 1994;18:344-351.
2. Arbab AS, Aoki S, Toyama K, et al. Quantitative measurement of regional cerebral blood flow with flow-sensitive alternating inversion recovery imaging: comparison with [iodine 123]iodoamphetamine single photon emission CT. Am J Neuroradiol. 2002;23:381-388.
3. Rostrup E, Larsson HB, Tofts PB, et al. Susceptibility contrast imaging of CO2-induced changes in the blood volume of the human brain. Acta Radiol. 1996;37:813-822.
4. Kleinschmidt A, Steinmetz H, Sitzer M, et al. Magnetic resonance imaging of cerebral oxygenation changes under acetazolamide in carotid occlusive disease. Stroke. 1995;26:106-110.
5. Hedera P, Lai S, Lewin JS, et al. Assessment of cerebral blood flow reserve using functional magnetic resonance imaging. J Magn Reson Imaging. 1996;6:718-725.
6. Thulborn KR, Waterton JC, Matthews PM, et al. Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta. 1982;714:265-270.
7. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA. 1992;89:5675-5679.
8. Balaban RS, Taylor JF, Turner R. Effect of cardiac flow on gradient recalled echo images of the canine heart. NMR Biomed. 1994;7:89-95.
9. Abramovitch R, Dafni H, Smouha E, et al. In-vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: MRI of C6 rat glioma in nude mice. Cancer Res. 1999;59:5012-5016.
10. Lythgoe DJ, Williams SC, Cullinane M, et al. Mapping of cerebrovascular reactivity using BOLD magnetic resonance imaging. Magn Reson Imaging. 1999;17:495-502.
11. Vesely A, Sasano H, Volgyesi G, et al. MRI mapping of cerebrovascular reactivity using square wave changes in end-tidal pCO2. Magn Reson Med. 2001;45:1011-1013.
12. Kety SS, Schmidt CF. Effects of active hyperventilation on cerebral blood flow, cerebral oxygen consumption, cardiac output, and blood pressure of normal young men. J Clin Invest. 1948;25:107-119.
13. Grubb RL, Raichle ME, Eichling JO, et al. The effects of changes in PaCO2 on cerebral blood volume, blood flow, and vascular mean transit time. Stroke. 1974;5:630-639.
14. Adams WM, Laitt RD, Li KL, et al. Demonstration of cerebral perfusion abnormalities in moyamoya disease using susceptibility perfusion- and diffusion-weighted MRI. Neuroradiology. 1999;41:86-92.
15. Yamada I, Himeno Y, Nagaoka T, et al. Moyamoya disease: evaluation with diffusion-weighted and perfusion echo-planar MR imaging. Radiology. 1999;212:340-347.
16. Neeman M, Dafni H, Bukhari O, et al. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med. 2001;45:887-898.
17. Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging. 1999;10:903-907.
18. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a Gd-enhanced TurboFLASH subtraction technique. Radiology. 1994;193:777-781.
19. Barentsz JO, Jager GJ, van Vierzen PB, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MRI. Radiology. 1996;201:185-193.
20. Verstraete KL, De Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MRI-parametric 'first pass' images depict tissue vascularization and perfusion. Radiology. 1994;192:835-843.
21. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast-enhanced MRI of prostate cancer: correlation with morphology and tumor stage, histological grade and PSA. Clin Radiol. 2000;55:99-109.
22. Battegay E. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
23. Amoroso A, Del Porto F, Di Monaco C, et al. Vascular endothelial growth factor: a key mediator of neoangiogenesis: a review. Eur Rev Med Pharmacol Sci. 1997;1:17-25.
24. Endrich B, Vaupel P. The role of the micro-circulation in the treatment of malignant tumours: facts and fiction. In: Molle M, Vaupels P, eds. Blood Perfusion and Microenvironment of Human Tumours. Berlin: Springer, 1998:19-39.
25. Dachs GU, Chaplin DJ. Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol. 1998;8:208-216.
26. Winlaw DS. Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg. 1997;64:1204-1211.
27. Roberts TPL. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging. 1997;7: 82-90.
28. Roberts TPL. Technical and practical considerations for permeability modeling of dynamic contrast enhanced MRI. Acad Radiol. 2004 (in press).
29. Pruessman K, Weiger M, Scheidegger MB, et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med. 1999;42:952-962.
30. Larsson H, Stubgaard M, Frederiksen J, et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990; 16:117-131.
31. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15: 621-628.
32. Tofts PS, Kermode AG. Measurement of the blood brain barrier permeability and leakage space using dynamic MR imaging: fundamental concepts. Magn Reson Med. 1991;17:357-367.
33. Bassingthwaighte JB, Goresky CA. Modeling in the analysis of solute and water exchange in the microvasculature. In: Renkin EM, Michel CC, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, MD: American Physiological Society, 1984:549-626.
34. Huang SC, Phelps ME. Principles of tracer kinetic modeling in positron emission tomography and autoradiography. In: Phelps ME, Mazziotta J, Schelbert H, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York: Raven Press, 1986:287-346.
35. Roberts HC, Roberts TPL, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899.
36. Kassner A, Roberts TPL, Taylor K, et al. Detection of Blood Brain Barrier Leakage in Early Acute Stroke Using Dynamic Contrast-Enhanced MRI. Kyoto: ISMRM, 2004.
37. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol. 1998;171:941-949.
38. Su MY, Wang Z, Carpenter PM, et al. Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents. J Magn Reson Imaging. 1999;9:177-186.
39. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology. 1999;213:265-272.
40. Pham CD, Roberts TPL, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 1998;16:225-230.
41. Brasch R, Pham CD, Shames DM, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging. 1997;7:68-74.
42. Roberts TPL, Turetschek K, Preda A, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol. Suppl. 2002;2:511-513.
43. Simonsen CF, Ostergaard L, Vestergaard-Poulsen P, et al. CBF and CBV Measurements by Bolus Tracking of an Iron Based CA. Sydney: ISMRM, 1998.
44. Turetschek K, Roberts TPL, Floyd E, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging. 2001;13:882-888.
45. Turetschek K, Huber S, Floyd E, et al. 2001 MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001;218:562-569.
46. Kennan RP, Zhong J, Gore JC. Intravascular susceptibility mechanisms in tissues. Magn Reson Med. 1994;31:9.
47. Helbich TH, Roberts TPL, Rollins MD, et al. Noninvasive assessment of wound-healing angiogenesis with contrast-enhanced MRI. Acad Radiol. Suppl. 1. 2002:145-147.